Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) P/E ratio
As of 5 November 2026, Johnson & Johnson (JNJ) trades at a P/E ratio of 41.3×. Over the past ten years it has ranged from 9.5× (May 2024) to 380× (January 2018); the current reading is higher than 92% of that period. That is above the Drug Manufacturers General industry median of 26.6× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 18.7× | (24.87%) |
| FY2024 | 24.9× | 115.20% |
| FY2023 | 11.6× | (56.19%) |
| FY2022 | 26.4× | 20.70% |
| FY2021 | 21.9× | (23.31%) |
| FY2020 | 28.6× | 10.34% |
| FY2019 | 25.9× | 12.53% |
| FY2018 | 23.0× | (93.56%) |
| FY2017 | 357× | 1,712.12% |
| FY2016 | 19.7× | 5.29% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 40.1× | 36.30% |
| Jun 2026 | 29.4× | 4.14% |
| Mar 2026 | 28.3× | 50.89% |
| Dec 2025 | 18.7× | 4.64% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| AZN AstraZeneca PLC compare | 26.3× |
| AMGN Amgen Inc. compare | 26.6× |
| NVS Novartis AG compare | 30.9× |
| JNJ Johnson & Johnson | 41.3× |
| PFE Pfizer Inc. compare | 42.2× |
| LLY Eli Lilly and Company compare | 44.5× |
| ABBV AbbVie Inc. compare | 49.7× |
| MRK Merck & Co., Inc. compare | 118× |
| Drug Manufacturers General industry median | 26.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement